{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054492","form_type":"8-K","ticker":null,"cik":"0001444380","company_name":"NEVRO CORP","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.449688+00:00","generated_at":"2026-06-02T17:28:17.251281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nevro Q1 revenue $101.9M (+5.8%), net loss $35.8M; raises adjusted EBITDA guidance, promotes Christoforou to COO","bullets":["Q1 2024 worldwide revenue $101.9M, up 5.8% YoY; net loss from operations $35.8M; adjusted EBITDA loss $9.6M.","FY2024 revenue guidance reaffirmed at $435–445M; adjusted EBITDA guidance raised to loss $5M to profit $2M.","Additional restructuring steps announced to accelerate profitability and strengthen operations.","Christofer Christoforou promoted to newly created COO role; he has been with Nevro for eight years.","SI joint business: over 220 physicians trained on Nevro1™, one of three SI joint products."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054492","json":"https://secwatch.observer/filing/0000950170-24-054492.json","markdown":"https://secwatch.observer/filing/0000950170-24-054492.md","text":"https://secwatch.observer/filing/0000950170-24-054492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/nvro-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:28:17.251281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37c815211c42aa98ad2d845f99a3a83168327f12","claim":"NEVRO CORP updated its full-year 2024 guidance (raised).","evidence_excerpt":"reaffirming our revenue guidance of $435 million to $445 million for the full-year 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"37c815211c42aa98ad2d845f99a3a83168327f12","claim":"NEVRO CORP updated its full-year 2024 guidance (raised).","evidence_excerpt":"raising our adjusted EBITDA guidance to a range of a loss of $5 million to positive $2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7e0cbb0123401d35d94f58ec4db511b18d03d172","claim":"NEVRO CORP reported first quarter 2024 results: revenue $101.9 million, net income loss of $35.8 million.","evidence_excerpt":"Worldwide revenue grew to $101.9 million, an increase of 5.8% as reported and 5.6% on a constant currency basis.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024054492/0000950170-24-054492-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$101.9 million"},{"label":"Net income","value":"loss of $35.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}